Categories Earnings, Health Care

CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot

— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share

— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected

— Net loss before recognition of the deemed dividends was $5.3 million

— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018

— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin

— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Key metrics from Nike’s (NKE) Q2 2025 earnings results

NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net

FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips

Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top